Video Series

Being able to tolerate intensive chemotherapy is not the same as benefiting from it. The panel weighs psychosocial realities and candid case outcomes in older patients with AML.

Even with consolidation immunotherapy, most limited-stage patients still recur, a reminder that biomarker-driven approaches, earlier detection, and next-generation agents remain essential to moving survival further.

The 11 micromolar target was built on epidemiologic reasoning rather than a normal range. Pending trials of higher doses and longer-acting agents may show whether raising levels further improves outcomes.

Logistics, not efficacy, often decide who completes limited-stage treatment. Distance from infusion centers, caregiver support, and clinic workflows can matter as much as the medicine itself in determining outcomes.

Looking ahead, Dr. Citrome weighs how payers should structure formulary access today against the long-term evidence still missing on treatment duration and relapse risk.

Four plasma-derived products deliver the same purified protein and appear clinically interchangeable. Differences in formulation, administration, and coverage design shape which product a patient actually receives.

Adherence depends on clear explanation, reliable inhaler technique, and affordable medication, and gaps in any one of these can quietly erode the benefit of an effective treatment plan.

Vitiligo begins with oxidative stress and ends with CD8-positive T cells destroying melanocytes that cannot easily regenerate. Dr. Hamzavi maps the autoimmune cascade and the disease associations clinicians should watch for.

Vitiligo affects up to two percent of the population worldwide, yet payers and patients alike still misread it as cosmetic. Dr. Desai explains the autoimmune biology, systemic comorbidities, and diagnostic pitfalls that argue otherwise.

Despite a clear survival benefit, a meaningful share of eligible patients never receive consolidation immunotherapy after chemoradiation, exposing a gap between what trial data supports and what real-world practice actually delivers.

The ADRIATIC trial reshaped limited-stage treatment, extending median survival by nearly two years with consolidation immunotherapy, a shift so significant that adherence, not efficacy, is now the field's central clinical challenge.

Cardioembolic stroke produces more severe strokes, greater disability, higher mortality, and frequent recurrence than other subtypes. Dr. Barnes reviews the outcome data that make prevention a clinical priority.

A teenager's first abscess can start a years-long cycle of misdiagnosis, shame, and fragmented care. Dr. Lev-Tov traces how untreated HS derails lives and strains both families and the healthcare system.

Separate risk systems now guide intensive and lower-intensity AML therapy, and objective fitness criteria are replacing the eyeball test in deciding which patients should receive which approach.

HS is far more common than most clinicians realize, and its origins are multifactorial. Understanding genetic, mechanical, microbial, and hormonal contributors gives clinicians a practical foundation for designing treatment plans.

Welcome back to another AJMC Insights series. In "Cardioembolic Stroke in AFib: Defining the Subtype and Its Mechanism," Dr. Barnes joins us to open the series on cardioembolic stroke in atrial fibrillation.

Acute myeloid leukemia arises from stem cell mutations and clonal expansion, and while diagnosis is rarely in doubt, genetic testing now shapes every treatment decision that follows.

Cost data in AATD depend heavily on how patients are identified. Augmentation therapy adds a substantial burden, yet survival benefit and comorbidity management complicate any simple cost comparison for payers.

An independently conducted meta-analysis confirms similar efficacy but surfaces a notable acceptability gap, underscoring why shared decision-making and patient preference remain central to prescribing.

Clinicians cannot be expected to remember every rare disease. Default order sets, testing tied to pulmonary function results, and standardized genotyping can make AATD testing the easy choice rather than an added burden.

Current biologics halve exacerbations but achieve remission in a minority of patients, and adherence often falters before therapy begins or around the 6-month mark.

Biologics can offset their acquisition cost by preventing exacerbations and cumulative steroid toxicity, yet billing structures and prior authorization continue to delay patients who need treatment.

The same AAT level can mean very different protease burdens in two patients. Severe deficiency drives the highest risk, yet carriers and unusual alleles complicate any simple relationship between numbers and disease.

The study's own senior author walks through its design, then reveals meaningful differences in weight gain, akathisia, and sedation risk that should inform how clinicians and payers evaluate these agents.

Decades of guidelines have recommended testing every patient with COPD, yet testing remains rare. The panel examines who gets missed, why clinicians believe they can spot AATD, and what health plans can do.

Asthma costs extend well beyond the emergency department, into lost schooling, reduced earning potential, and steroid harm, which sharpens the case for recognizing uncontrolled disease and escalating care promptly.

Most patients with asthma carry a type 2 inflammatory signature, and the sickest fifth of them account for the bulk of an $80 billion annual burden.

Led by the moderator, the panelists examined the core lessons from the series.